[company_age]1.0[/company_age][employees]2-10 employees[/employees][funding]Series A[/funding][description]NewBiologix is a Swiss technology innovation company specializing in developing a proprietary DNA integration platform for advanced human and mammalian cell line engineering. Their focus lies on improving the generation and production of viral vectors used in gene and cell therapies. They achieve this by combining an innovative bioinformatics platform with advanced R&D experimentation. NewBiologix aims to address the surging demand for economically viable, large-scale production of viral vectors for gene therapy, thereby assisting partners in developing advanced therapy medicinal products (ATMPs) for rare, chronic, and incurable diseases. Their approach challenges the manufacturing status quo by relying on disruptive and transformative technologies instead of legacy processes. This commitment to innovation is evident in their groundbreaking DNA integration platform, which sets them apart from competitors.[/description][ps]DNA integration platform for advanced human and mammalian cell line engineering[/ps]